IntraBio
Private Company
Funding information not available
Overview
IntraBio is a clinical-stage biotech developing IB1001 (N-acetyl-L-leucine), an oral modified amino acid, for rare neurological disorders. Its lead program for Niemann-Pick disease type C (NPC) has reported positive Phase III results, and the company has achieved its first FDA approval with AQNEURSA™ (levacetylleucine) for an undisclosed indication. The company leverages a scientific foundation from key academic institutions and is advancing a pipeline targeting common neurological disorders and healthspan.
Technology Platform
Platform based on orally administered modified amino acids (e.g., N-acetyl-L-leucine) designed to correct metabolic dysfunction, improve lysosomal function, and enhance mitochondrial function/ATP production.
Opportunities
Risk Factors
Competitive Landscape
In NPC, competition is limited as there are no globally approved disease-modifying therapies, though other investigational approaches exist. The broader landscape for rare neurological diseases is competitive, with many biopharma companies pursuing gene therapies, enzyme replacements, and other small molecules. Expansion into common disorders would face intense competition from large pharma.